Warkentin TE, Sheppard JI, Moore JC, Sigouin CS, Kelton JG. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost. 2008;6(8):1304–12.
Article CAS PubMed Google Scholar
Warkentin TE, Sheppard JAI. Testing for heparin-induced thrombocytopenia antibodies. Transfus Med Rev. 2006;20(4):259–72.
Zwicker JI, Uhl L, Huang WY, Shaz BH, Bauer KA. Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost. 2004;2(12):2133–7.
Article CAS PubMed Google Scholar
Wallis DE, Workman DL, Lewis BE, Steen L, Pifarre R, Moran JF. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med. 1999;106(6):629–35.
Article CAS PubMed Google Scholar
Rice L. Cases of heparin-induced thrombocytopenia elucidate the syndrome. Chest. 2005;127(2):21S-26S.
Visentin GP, Moghaddam M, Beery SE, McFarland JG, Aster RH. Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis. J Lab Clin Med. 2001;138(1):22–31.
Article CAS PubMed Google Scholar
Eichler P, Raschke R, Lubenow N, Meyer O, Schwind P, Greinacher A. The new ID-heparin/PF4 antibody test for rapid detection of heparin-induced antibodies in comparison with functional and antigenic assays: ID-heparin/PF4 antibody test for detection of HIT antibodies. Br J Haematol. 2002;116(4):887–91.
Article CAS PubMed Google Scholar
Legnani C, Cini M, Pili C, Boggian O, Frascaro M, Palareti G. Evaluation of a new automated panel of assays for the detection of anti-PF4/heparin antibodies in patients suspected of having heparin-induced thrombocytopenia. Thromb Haemost. 2010;104(08):402–9.
Article CAS PubMed Google Scholar
Juhl D, Eichler P, Lubenow N, Strobel U, Wessel A, Greinacher A. Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia. Eur J Haematol. 2006;76(5):420–6.
Francis J. A critical evaluation of assays for detecting antibodies to the heparin-PF4 complex. Semin Thromb Hemost. 2004;30(03):359–68.
Article CAS PubMed Google Scholar
Padmanabhan A, Jones C, Curtis BR, Bougie DW, Sullivan M, Peswani N, et al. A novel PF4-dependent platelet activation assay identifies patients likely to have heparin-induced thrombocytopenia/thrombosis (HIT). Blood. 2015;126(23):764–764.
Marchetti M, Zermatten MG, Bertaggia Calderara D, Aliotta A, Alberio L. Heparin-induced thrombocytopenia: a review of new concepts in pathogenesis, diagnosis, and management. J Clin Med. 2021;10(4):683.
Article CAS PubMed PubMed Central Google Scholar
Greinacher A. Heparin-induced thrombocytopenia. Solomon CG, editor. N Engl J Med. 2015;373(3):252–61.
Article CAS PubMed Google Scholar
Warkentin TE, Anderson JAM. How I treat patients with a history of heparin-induced thrombocytopenia. Blood. 2016;128(3):348–59.
Article CAS PubMed Google Scholar
Arepally GM, Ortel TL. Heparin-induced thrombocytopenia. Annu Rev Med. 2010;61(1):77–90.
Article CAS PubMed PubMed Central Google Scholar
Cuker A, Cines DB. How I treat heparin-induced thrombocytopenia. Blood. 2012;119(10):2209–18.
Article CAS PubMed Google Scholar
Thorevska N, Amoateng-Adjepong Y, Sabahi R, Schiopescu I, Salloum A, Muralidharan V, et al. Anticoagulation in hospitalized patients with renal insufficiency. Chest. 2004;125(3):856–63.
Article CAS PubMed Google Scholar
Hughes S, Szeki I, Nash MJ, Thachil J. Anticoagulation in chronic kidney disease patients—the practical aspects. Clin Kidney J. 2014;7(5):442–9.
Article CAS PubMed PubMed Central Google Scholar
Warkentin TE, Pai M, Linkins LA. Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review. Blood. 2017;130(9):1104–13.
Article CAS PubMed Google Scholar
Tardy-Poncet B, Piot M, Montmartin A, Burdier A, Chalayer E, Tardy B. Delayed-onset heparin-induced thrombocytopenia without thrombosis in a patient receiving postoperative thromboprophylaxis with rivaroxaban. Thromb Haemost. 2015;114(09):652–4.
Linkins LA, Warkentin TE, Pai M, Shivakumar S, Manji RA, Wells PS, et al. Rivaroxaban for treatment of suspected or confirmed heparin-induced thrombocytopenia study. J Thromb Haemost. 2016;14(6):1206–10.
Article CAS PubMed Google Scholar
Sharifi M, Bay C, Vajo Z, Freeman W, Sharifi M, Schwartz F. New oral anticoagulants in the treatment of heparin-induced thrombocytopenia. Thromb Res. 2015;135(4):607–9.
Article CAS PubMed Google Scholar
Larsen PB, Jørgensen M, Friis-Hansen L, Ingeberg S. Apixaban used for the management of heparin-induced thrombocytopenia in a 72-year-old woman with lung cancer. Clin Case Rep. 2015;3(12):987–9.
Article PubMed PubMed Central Google Scholar
Delgado-García G, Monreal-Robles R. Acute apixaban treatment of heparin-induced thrombocytopenia. J Thromb Thrombolysis. 2017;43(3):289–90.
Anniccherico FJ, Alonso JL. Dabigatran for heparin-induced thrombocytopenia. Mayo Clin Proc. 2013;88(9):1036.
Noel E, Abbas N, Skaradinskiy Y, Schreiber Z. Heparin-induced thrombocytopenia in a patient with essential thrombocythemia: a case based update. Case Rep Hematol. 2015;2015:1–5.
Cuker A, Arepally GM, Chong BH, Cines DB, Greinacher A, Gruel Y, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018;2(22):3360–92.
Article CAS PubMed PubMed Central Google Scholar
Altuntas F, Matevosyan K, Burner J, Shen YM, Sarode R. Higher optical density of an antigen assay predicts thrombosis in patients with heparin-induced thrombocytopenia. Eur J Haematol. 2008;80(5):429–35.
Baroletti S, Hurwitz S, Conti NAS, Fanikos J, Piazza G, Goldhaber SZ. Thrombosis in suspected heparin-induced thrombocytopenia occurs more often with high antibody levels. Am J Med. 2012;125(1):44–9.
Article CAS PubMed Google Scholar
Warkentin T, Hayward C, Boshkov L, Santos A, Sheppard J, Bode A, et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood. 1994;84(11):3691–9.
Article CAS PubMed Google Scholar
Arman M, Krauel K. Human platelet IgG Fc receptor FcγRIIA in immunity and thrombosis. J Thromb Haemost. 2015;13(6):893–908.
留言 (0)